# Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.

> **NCT04324021** · PHASE2,PHASE3 · TERMINATED · sponsor: **Swedish Orphan Biovitrum** · enrollment: 16 (actual)

## Conditions studied

- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** Emapalumab
- **BIOLOGICAL:** Anakinra

## Key facts

- **NCT ID:** NCT04324021
- **Lead sponsor:** Swedish Orphan Biovitrum
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-02
- **Primary completion:** 2020-11-13
- **Final completion:** 2020-11-13
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Standard of care evolved during the timeframe of the study and had critical impact on recruitment.

Early termination was not based on safety reasons but due to the reasons mentoined above.

The ongoing patients were completed.
- **Last updated:** 2022-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04324021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04324021, "Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04324021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*